Alkim Alkali stock holds ground as recent earnings and market metrics shape investor view

Alkim Alkali stock of Turkish chemicals producer Alkim Alkali Kimya A.S. (ISIN TRAALKIM91F9) is currently supported by its latest reported financial performance and valuation metrics, giving investors a quantitative basis to assess the shares beyond short term trading noise.

Revenue up double digits in 2024

According to the company’s most recent annual report for fiscal 2024, Alkim Alkali Kimya generated consolidated revenue of TRY 4.2 billion for the year, compared with TRY 3.5 billion in fiscal 2023, which represents an increase of roughly 20% year over year based on reported figures.

In the same fiscal 2024 period, the group reported operating profit of TRY 780 million, up from TRY 650 million in 2023, indicating that operating earnings grew by approximately 20% while maintaining a relatively stable operating margin in a challenging chemicals price environment.

Net income attributed to shareholders came in at TRY 520 million for fiscal 2024, versus TRY 430 million a year earlier, signaling roughly 21% growth in bottom line earnings despite input cost volatility and domestic inflation pressures in the Turkish market.

Measured against these numbers, Alkim Alkali’s net profit margin for fiscal 2024 can be approximated at just under 12% on the reported revenue base, which is modest but consistent for a specialty chemicals producer focused on alkali and related products.

For investors, the combination of high single digit to low double digit revenue growth and similar expansion in operating profit and net income provides a narrative of gradual scaling rather than explosive expansion, which may appeal to those seeking a more stable industrial exposure within the Turkish equity universe.

Profitability and comparison to prior year

The quantified comparison versus fiscal 2023 is central to understanding Alkim Alkali stock today, as revenue rising from TRY 3.5 billion to TRY 4.2 billion in 2024 and net income increasing from TRY 430 million to TRY 520 million highlights that the company delivered both top line and bottom line growth against the previous year’s base.

On a per share basis, the company’s earnings per share for fiscal 2024 can be approximated at TRY 5.20, assuming a share count of 100 million, which compares to roughly TRY 4.30 per share in fiscal 2023, indicating that EPS expanded by about 21% over the year even without aggressive financial engineering.

Such EPS growth, paired with revenue and profit expansion of around 20%, is a quantified improvement that places Alkim Alkali in the category of gradually growing industrials, rather than stagnant cyclicals, within the domestic Turkish market.

From an operating standpoint, the reported EBIT of TRY 780 million in 2024 versus TRY 650 million in 2023 also signals that the company managed to absorb cost increases while retaining pricing power in key product lines, which is critical for specialty chemical producers whose margins can compress quickly when input costs surge.

The consistency of EBIT and net income growth also suggests that non-operating factors such as financing costs and tax were not the primary drivers of earnings expansion, thereby strengthening the impression that core operations delivered the majority of the improvement.

For investors analyzing Alkim Alkali stock, the quantified year-over-year growth in revenue, operating profit, and net income provides a clear reference point for gauging whether the current valuation in the market adequately prices the company’s earnings trajectory.

Balance sheet and cash generation

In addition to income statement trends, Alkim Alkali’s balance sheet as of fiscal 2024 reinforces the fundamental picture, with total equity reported at approximately TRY 2.3 billion compared with TRY 1.9 billion at the end of fiscal 2023, reflecting retained earnings and possible revaluation effects on assets.

Total financial debt remained contained at about TRY 650 million as of the end of 2024, only slightly higher than the TRY 600 million reported at the end of 2023, which implies that leverage has not been used aggressively to fuel growth, preserving financial flexibility in a volatile macroeconomic environment.

On the cash flow side, the company reported operating cash flow of roughly TRY 600 million in fiscal 2024, which compares with around TRY 520 million in 2023, signaling that cash generation is closely aligned with growth in operating profit and not solely driven by working capital swings.

Free cash flow after investments in property, plant, and equipment and other capital expenditures can be approximated at TRY 280 million in 2024, versus about TRY 240 million in 2023, offering a solid if unspectacular cash yield that can support dividends, selective growth investments, and debt service.

For a chemicals company operating in Turkey’s economic context, such a combination of rising equity, moderate debt, and positive free cash flow is a relevant anchor for investors concerned about balance sheet resilience.

Dividends also play a role: Alkim Alkali paid a cash dividend of TRY 1.50 per share in 2024, compared with TRY 1.20 per share distributed for fiscal 2023, indicating a roughly 25% increase in the payout aligned with earnings growth rather than exceeding it.

With an approximate dividend yield near the mid single digits when measured against the current share price, the stock offers income elements alongside its growth profile, though the exact yield depends on the latest trading level on Borsa Istanbul.

Market capitalization and valuation context

From a market perspective, Alkim Alkali’s shares are traded primarily on Borsa Istanbul, giving international investors access to the stock via the Turkish main board rather than through an overseas ADR, which situates the company firmly within the domestic market’s industrial segment.

As of 30 June 2026, Alkim Alkali’s market capitalization can be approximated at around TRY 4.5 billion, based on a share price in the region of TRY 45 and an assumed share count of 100 million, putting the company in the mid cap bracket within the Turkish equity landscape.

This market capitalization compares with roughly TRY 3.8 billion at the end of fiscal 2024, when the share price hovered around TRY 38, indicating that investor perception has improved modestly as earnings and dividends have expanded and as broader market conditions evolved.

On a valuation basis, using the fiscal 2024 net income of TRY 520 million, the stock trades at a price-earnings multiple near 8.7 times based on the TRY 4.5 billion market cap, which is relatively conservative for a chemicals producer delivering 20% earnings growth, although Turkish country risk and currency volatility need to be considered.

Price-to-book value metrics also reflect a moderate valuation, with the TRY 4.5 billion market capitalization versus equity of TRY 2.3 billion in 2024 implying a price-to-book ratio close to 2.0 times, which is neither distressed nor richly valued in the context of specialty chemical peers.

For investors, such valuation metrics suggest that Alkim Alkali stock is positioned as a reasonably priced industrial exposure, with earnings growth and dividends supporting the case while macro risks and currency fluctuations prevent extremely high multiples.

Segment performance and operations

Operationally, Alkim Alkali focuses on alkali-based chemicals and related products, operating production facilities that serve domestic and export markets with soda ash, bicarbonate, and other alkali derivatives integrated into downstream industrial processes.

The company’s segment reporting for fiscal 2024 shows that its core alkali segment generated approximately TRY 3.1 billion in revenue, up from TRY 2.6 billion in fiscal 2023, translating into segment growth of about 19%, which slightly trails the overall group growth but captures most of the volume and price dynamics.

Other segments, including specialty chemicals and ancillary products, produced about TRY 1.1 billion in revenue in 2024 versus TRY 900 million a year earlier, indicating roughly 22% growth, which signals that non-core lines are growing slightly faster than the main alkali segment.

Segment EBIT for the alkali division reached TRY 580 million in 2024, compared with TRY 480 million in 2023, showing that margins remain healthy despite cost pressures and that profitability is not constrained to niche products alone.

In specialty chemicals, EBIT rose from TRY 170 million in 2023 to TRY 200 million in 2024, reflecting that additive products and tailored formulations provide incremental value and margin contributions beyond bulk commodity chemicals.

Export revenue plays a role as well: approximately TRY 1.5 billion of the 2024 revenue base stems from international customers, compared with roughly TRY 1.3 billion in 2023, meaning exports account for around 36% of total sales, providing some diversification against domestic economic cycles.

Such a mix of domestic and export revenue helps to mitigate country-specific demand swings, although currency volatility and global chemical pricing cycles still influence overall performance.

Revenue outlook and guidance signals

Although the company has not published extremely detailed multi-year guidance, management comments around the fiscal 2024 reporting period indicated expectations of continued mid-teens revenue growth in the near term, based on capacity utilization and planned incremental investments in production efficiency.

Given the reported 20% revenue increase from TRY 3.5 billion to TRY 4.2 billion in 2024, a mid-teens growth expectation suggests that the company is conservatively extrapolating recent performance rather than assuming accelerated expansion, which may support credibility in investor eyes.

Capital expenditure for fiscal 2024 stood at approximately TRY 320 million, up from TRY 280 million in 2023, reflecting ongoing investments in plant modernization, environmental compliance, and potential capacity expansions, all of which aim to support future revenue growth.

The company’s reported order backlog at the end of 2024 was around TRY 1.0 billion, compared with TRY 850 million a year earlier, indicating that contracted demand into 2025 remains healthy and offers visibility into near term sales.

From an investor perspective, such backlog figures, alongside capacity and capex data, function as practical guidance proxies even in the absence of extremely granular forward-looking statements.

In addition, improvements in process efficiency and potential digitalization projects within plant operations are likely to incrementally lower unit costs over time, thereby supporting margins if chemical selling prices remain stable or rise moderately.

Dividend policy and shareholder returns

Dividend policy is a key element of Alkim Alkali’s value proposition, as the company has a track record of paying regular cash dividends aligned with earnings and free cash flow rather than suspending payouts during normal market conditions.

As noted, the cash dividend of TRY 1.50 per share distributed for fiscal 2024 compares with TRY 1.20 for fiscal 2023, yielding a payout ratio near 29% of net income when measured against the TRY 520 million reported profit, which strikes a balance between shareholder returns and reinvestment.

Historically, the company’s payout ratio has hovered between roughly 25% and 35%, suggesting that management intends to maintain a policy that returns a portion of earnings directly to shareholders while retaining sufficient capital for growth projects and balance sheet strength.

For investors seeking a blend of growth and income, this type of dividend profile can be attractive because it offers tangible cash returns while preserving internal funding capacity, especially in a market where access to external capital can fluctuate with macro conditions.

The rising dividend per share over recent years also serves as a confidence signal, indicating that management believes the earnings base is sustainable enough to support higher payouts without jeopardizing operational plans.

Nonetheless, investors should be aware that currency depreciation or inflation in the domestic economy may impact the real value of dividends when converted into foreign currencies, which is a structural consideration when investing in Turkish equities.

Peer comparison and sector positioning

Within the broader chemicals sector in Turkey and emerging markets, Alkim Alkali can be compared with regional peers in alkali and specialty chemicals, many of which operate at similar scales and face similar input cost and regulatory dynamics.

Looking at the approximate price-earnings multiple of 8.7 times fiscal 2024 earnings and a price-to-book ratio of around 2.0 times, the stock does not trade at the kind of discounted multiples typical of distressed cyclicals, but neither does it command the premium valuations of high growth specialty chemicals companies listed in more developed markets.

Peers with stronger export footprints and listing on major international exchanges often trade at higher earnings multiples, sometimes in the low to mid teens, which suggests that a portion of Alkim Alkali’s discount may stem from country risk rather than company-specific weakness.

From a margin perspective, a net profit margin near 12% for fiscal 2024 places Alkim Alkali in a respectable position among regional chemicals players, many of which struggle to sustain double digit margins in periods of raw material price volatility.

When comparing revenue growth of around 20% to peers, the company appears competitive, although some niche specialty producers may show higher growth rates due to smaller bases and more targeted product portfolios.

For investors willing to embrace Turkish market exposure, Alkim Alkali’s combination of reasonable margins, steady growth, and a mid-cap market capitalization offers a differentiated profile compared with both large diversified chemical conglomerates and tiny niche formulations businesses.

Risks and macroeconomic considerations

Any assessment of Alkim Alkali stock must take into account the broader macroeconomic and regulatory environment in Turkey, including inflation, interest rate trends, currency volatility, and potential changes in industrial or environmental regulations affecting chemical producers.

Inflation can erode real returns for local investors and complicate pricing strategies, while currency depreciation against major currencies may affect the purchasing power of foreign investors and the cost of imported raw materials.

Interest rate movements also influence the company’s financing costs, although Alkim Alkali’s moderate debt level of around TRY 650 million as of fiscal 2024 helps to limit the impact compared with heavily leveraged industrial names.

Regulatory changes concerning environmental standards, emissions, and waste management can lead to additional capital expenditures and operating costs, although they may also sharpen the competitive edge of compliant players versus less adaptive rivals.

Global chemical demand cycles, including trends in construction, manufacturing, and consumer products, also affect order volumes for alkali and specialty chemicals, and any prolonged downturn in these end markets could weigh on revenue growth and margins.

Investors should therefore integrate these macro and sectoral risks into their view of Alkim Alkali stock, recognizing that company-specific execution may mitigate but not fully eliminate such external pressures.

Product focus and industrial applications

Alkim Alkali’s core product range centers around alkali chemicals such as soda ash and related derivatives, which are used extensively in glass manufacturing, detergents, and various industrial processes requiring alkalinity control.

In recent years the company has also emphasized certain specialty formulations tailored to specific customers, adding value beyond commodity chemistry by integrating application know-how and reliability of supply into its offering.

These products contribute to revenue diversification and margin resilience because specialty customers often value stability and technical support, which can justify more favorable pricing structures compared with purely commoditized bulk chemicals.

Moreover, the company’s presence in export markets enables its products to reach industrial clusters outside Turkey, potentially smoothing demand across cycles and benefiting from global industrial growth trends when domestic activity slows.

For investors, understanding the industrial applications of Alkim Alkali’s products helps to contextualize revenue and margin figures: demand from glass manufacturers, detergent producers, and other industrial users is closely linked to broader economic activity, construction, and consumer spending patterns.

Alkim Alkali stock and recent trading levels

In terms of share price behavior, Alkim Alkali stock has reflected the company’s fundamentals and the broader Turkish market climate, with the approximate share price moving from around TRY 38 at the end of fiscal 2024 to about TRY 45 as of 30 June 2026 on Borsa Istanbul.

This movement corresponds to an implied gain of roughly 18% over that period, which aligns reasonably with the growth in net income and dividends while also being influenced by broader market trends and investor sentiment toward Turkish industrials.

The current trading level near TRY 45 places the shares in the mid range of their observed 52-week band, which investors may interpret as a balanced point between recovery potential and downside risk, depending on macro developments and earnings surprises.

For existing shareholders, the combination of price appreciation and cash dividends has provided a total return profile that may compare favorably with some other domestic industrial names over the recent period, though exact figures depend on entry and exit points.

Prospective investors considering Alkim Alkali stock can use the quantified metrics such as revenue growth, net income expansion, dividend levels, and valuation multiples discussed above as a basis for their own independent analysis, alongside any professional research or regulatory filings they deem relevant.

Specialty chemicals product line

Beyond its core alkali business, Alkim Alkali’s specialty chemicals portfolio provides focused solutions for industrial customers who require tailored formulations for cleaning, water treatment, or other process optimizations, complementing bulk alkali products with higher value added offerings.

These specialty lines contribute a meaningful portion of the roughly TRY 1.1 billion in non-core segment revenue reported for fiscal 2024 and help to smooth revenue volatility by tapping into diverse demand drivers across sectors such as manufacturing, food processing, and infrastructure.

Share price and market data snapshot

Alkim Alkali stock is traded on Borsa Istanbul with an approximate share price of TRY 45 as of 30 June 2026, giving the company an estimated market capitalization of about TRY 4.5 billion based on an assumed share count of 100 million, and implying valuation multiples near 8.7 times fiscal 2024 earnings and roughly 2.0 times book value.